Who are Kolbet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Synthroid, Aramine, levothyroxin, Thyroxine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iguratimod.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Kolbet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kolbet (IGURATIMOD) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Macrophage migration inhibitory factor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Kolbet (IGURATIMOD).

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kolbet TARGET	IGURATIMOD		marketed		Macrophage migration inhibitory factor
Synthroid	levothyroxine	Generic (originally multiple — AbbVie/Synthroid)	marketed	Thyroid hormone	THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial	2002-08-13
Aramine	METARAMINOL		marketed	Indirectly Acting Sympathomimetic Amines	Macrophage migration inhibitory factor	1954-01-01
levothyroxin	levothyroxin	Ain Shams University	marketed		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Thyroxine	Thyroxine	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kolbet — Competitive Intelligence Brief. https://druglandscape.com/ci/iguratimod. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing